Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer

NCT06642545 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Disitamab Vedotin
DRUG: RC148
DRUG: Albumin-bound Paclitaxone
DRUG: Toripalimab

Sponsor

RemeGen Co., Ltd.